Acne Vulgaris Protocol

DermatologicalStrong Evidence

supplements

Primary

Supporting

Grade A

Studies

Primary Stack

Core supplements with strongest evidence

Nicotinamide (Vitamin B3)A

750-1500mg daily (or 4% topical)

Reduces sebum production, decreases inflammation via NF-κB inhibition, and strengthens skin barrier

↓Acne Symptoms↑Erythema↑Wound Healing

8 studies420 participants

Supporting Studies (2)

PMID: 8784881 - Topical nicotinamide vs clindamycin for acne (1995)PMID: 28220628 - Oral nicotinamide for inflammatory acne (2017)

ZincA

30-45mg daily (gluconate or picolinate)

Inhibits P. acnes growth, reduces inflammation, and decreases keratinocyte proliferation

↓Acne Symptoms

12 studies680 participants

Supporting Studies (2)

PMID: 11586012 - Zinc gluconate vs minocycline for inflammatory acne (2001)PMID: 28378879 - Efficacy of zinc in acne vulgaris: meta-analysis (2017)

Supporting Stack

Additional supplements for enhanced results

ProbioticsB

10-20 billion CFU daily (Lactobacillus strains)

Modulates gut-skin axis, reduces systemic inflammation, and may decrease sebum production

6 studies320 participants

Supporting Studies (1)

PMID: 28914266 - Probiotics for acne: systematic review (2018)

Omega-3 Fatty AcidsB

2g EPA/DHA daily

EPA reduces inflammatory prostaglandins and may decrease androgen-stimulated sebum production

5 studies180 participants

Supporting Studies (1)

PMID: 24553997 - Omega-3 fatty acids for acne vulgaris (2014)

How This Protocol Works

Simple Explanation

Acne develops when hair follicles become clogged with sebum (oil) and dead skin cells, creating an environment where Propionibacterium acnes bacteria thrive. This triggers inflammation, resulting in pimples, blackheads, and cysts. Hormones (especially androgens) increase sebum production, which is why acne often worsens during puberty.

•Nicotinamide (Vitamin B3) works on multiple fronts: it reduces sebum production, calms inflammation by blocking NF-κB signaling, and strengthens the skin barrier. Studies show it's as effective as topical antibiotics for inflammatory acne, without contributing to antibiotic resistance.

•Zinc has direct antibacterial effects against P. acnes and reduces the inflammatory response. It also helps regulate sebum production and skin cell turnover. Studies show oral zinc is nearly as effective as antibiotics for moderate acne.

•Probiotics address the gut-skin connection. Poor gut health increases systemic inflammation that can manifest as skin problems. Certain Lactobacillus strains have been shown to reduce acne lesion counts.

•Omega-3 fatty acids reduce inflammatory markers and may help balance the effects of omega-6 fatty acids that promote inflammation. Some evidence suggests they can decrease sebum production.

Expected timeline: Zinc and nicotinamide show improvement in 4-8 weeks. Probiotics may take 8-12 weeks. Full clearing typically takes 3-4 months of consistent use.

Clinical Perspective

Acne pathophysiology involves four key factors: excess sebum production (driven by androgens and IGF-1), follicular hyperkeratinization, Cutibacterium acnes (formerly P. acnes) proliferation, and inflammation mediated by TLR2 activation and IL-1/TNF-α release. This protocol targets inflammation and sebum production.

•Nicotinamide (A-grade): Inhibits sebocyte lipogenesis via SIRT1 activation. Blocks NF-κB nuclear translocation, reducing IL-8 and TNF-α production. Enhances ceramide synthesis strengthening stratum corneum. 8 studies with 420 participants show comparable efficacy to topical clindamycin (PMID: 8784881). Oral dosing 500mg TID shows 4x improvement rate.

•Zinc (A-grade): Inhibits 5-alpha reductase reducing DHT-stimulated sebum. Bacteriostatic against C. acnes via inhibition of lipase and ROS production. Reduces keratinocyte activation and inflammatory cytokine expression. 12 RCTs demonstrate 30mg elemental zinc comparable to 100mg minocycline (PMID: 11586012). Gluconate and picolinate forms best absorbed.

•Probiotics (B-grade): Lactobacillus and Bifidobacterium strains modulate gut-skin axis via reduced intestinal permeability and systemic inflammation. May produce bacteriocins with anti-C. acnes activity. 6 studies show reduced inflammatory lesion counts (PMID: 28914266). L. rhamnosus GG and L. acidophilus strains most studied.

•Omega-3 Fatty Acids (B-grade): EPA inhibits conversion of arachidonic acid to PGE2 and LTB4 (pro-inflammatory). May reduce IGF-1 signaling in sebocytes. 5 studies with 180 participants show improvement in inflammatory acne (PMID: 24553997).

Biomarker targets: Inflammatory lesion count, sebum production rate, inflammatory markers (IL-1β, IL-6).

Protocol notes: Zinc >40mg/day may cause copper deficiency—limit to 8-12 weeks at high doses or add 2mg copper. Topical nicotinamide 4% can be combined with oral. Address dietary factors: low glycemic index diet, dairy reduction may help.

View All Protocols